maryland physicians care
Medicaid with a Heart

PRIOR AUTHORIZATION REQUEST

Cosentyx

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for **ALL** PA requests.

1	Will the requested medication be used in combination with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)? [Note: Examples of biologics include but not limited to adalimumab SC products (for example, Humira, biosimilars), Actemra (IV or SC), Cimzia, Cosentyx, an etanercept SC product (for example, Enbrel, biosimilars), Ilumya, Skyrizi, Kevzara, Kineret, Orencia (IV or SC), an infliximab IV products (for example, Remicade, biosimilars), a rituximab IV products (for example, Rituxan, biosimilars), Siliq, Stelara (IV or SC), Taltz, Tremfya, Entyvio, or Simponi (Aria or SC), Examples of Targeted Synthetic Disease-Modifying Antirheumatic Drugs include but not limited to Cibinqo, Olumiant, Rinvoq, Otezla, Xeljanz, Xeljanz XR.] [If yes, no further questions.]	Yes	No

If you have any questions, call:
1-888-258-8250

PRIOR AUTHORIZATION REQUEST

2	Is the patient currently receiving the requested medication? [If no, skip to question 9.]	Yes	No
3	Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 9.]	Yes	No
4	Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 7.]	Yes	No
5	Has the patient been established on therapy for at least 3 months? [If no, skip to question 9.]	Yes	No
6	Has documentation been submitted to confirm that the patient has had a clinically significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [If yes, skip to question 8.] [If no, no further questions.]	Yes	No
7	Has documentation been submitted to confirm that the patient has had a clinically significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation [If yes, skip to question 9.] [If no, no further questions.]	Yes	No
8	What is the indication or diagnosis? [] Ankylosing spondylitis (If checked, no further questions) [] Enthesitis-related arthritis (If checked, no further question.) [] Non-radiographic axial spondyloarthritis (If checked, no further questions) [] Plaque psoriasis (If checked, no further questions) [] Psoriatic arthritis (If checked, no further questions) [] Hidradenitis suppurativa (If checked, no further questions) [] Crohn's disease (If checked, no further questions) [] Rheumatoid arthritis (If checked, no further questions) [] Uveitis (If checked, no further questions) [] All other indications/diagnosis (If checked, no further questions)		

If you have any questions, call: 1-888-258-8250

PRIOR AUTHORIZATION REQUEST

9	What is the indication or diagnosis? [] Ankylosing spondylitis (If checked, go to 10) [] Enthesitis-related arthritis (If checked, go to 13) [] Non-radiographic axial spondyloarthritis (If checked, go to 18) [] Plaque psoriasis (If checked, go to 23) [] Psoriatic arthritis (If checked, go to 28) [] Hidradenitis suppurativa (If checked, go to 35) [] Crohn's disease (If checked, no further questions) [] Rheumatoid arthritis (If checked, no further questions) [] Uveitis (If checked, no further questions) [] All other indications/diagnosis (If checked, no further questions)		
10	Has documentation been provided to confirm that the patient had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitors, Enbrel (etanercept) and an adalimumab product (Hadlima, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
11	Has documentation been provided to confirm that the patient had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred JAK inhibitor, Xeljanz? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
12	Is the requested medication being prescribed by or in consultation with a rheumatologist **?** [If yes, skip to question 34.] [If no, no further questions.]	Yes	No
13	Is the patient greater than or equal to 4 year(s) of age? [If no, no further questions.]	Yes	No
14	Has the patient tried at least one prescription strength systemic agent for at least 3 months? [Note: Examples of prescription strength systemic agents include NSAIDs such as ibuprofen and naproxen.] [If yes, skip to question 16.]	Yes	No
15	Has documentation been provided to confirm that the patient had an intolerance to	Yes	No

PRIOR AUTHORIZATION REQUEST

	at least two prescription strength systemic agents? [Note: Examples of prescription strength systemic agents include NSAIDs such as ibuprofen and naproxen.] [If no, no further questions.]		
16	Has documentation been provided to confirm that the patient had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitors, Enbrel (etanercept) and an adalimumab product (Hadlima, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
17	Is the requested medication being prescribed by or in consultation with a rheumatologist? [If yes, skip to question 34.] [If no, no further questions.]	Yes	No
18	Does the patient have a documented clinical diagnosis of non-radiographic axial spondyloarthritis? [If no, no further questions.]	Yes	No
19	Does the patient have an objective sign of inflammation defined as a C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory? [If yes, skip to question 21.]	Yes	No
20	Does the patient have an objective sign of inflammation defined as a sacroiliitis reported on magnetic resonance imaging? [If no, no further questions.]	Yes	No
21	Has documentation been provided to confirm that the patient had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitors, Enbrel (etanercept), an adalimumab product (Hadlima, Yusimry, or adalimumab-adbm), and Cimzia (certolizumab)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
22	Is the requested medication being prescribed by or in consultation with a rheumatologist? [If yes, skip to question 34.] [If no, no further questions.]	Yes	No
23	Is the patient greater than or equal to 6 year(s) of age? [If no, no further questions.]	Yes	No
24	Has the patient tried at least one traditional systemic agent for psoriasis for at least 3 months? [Note: Examples of traditional systemic agents for psoriasis include methotrexate, cyclosporine, acitretin tablets, or psoralen plus ultraviolet A light (PUVA).] [If yes, skip to question 26.]	Yes	No

PRIOR AUTHORIZATION REQUEST

25	Has documentation been provided to confirm that the patient had an intolerance to at least two traditional systemic agents? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of traditional systemic agents for psoriasis include methotrexate, cyclosporine, acitretin tablets, or psoralen plus ultraviolet A light (PUVA).] [If no, no further questions.]	Yes	No
26	Has documentation been provided to confirm that the patient had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitors, Enbrel (etanercept) and an adalimumab product (Hadlima, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
27	Is the requested medication being prescribed by or in consultation with a dermatologist? [If yes, skip to question 34.] [If no, no further questions.]	Yes	No
28	Is the patient greater than or equal to 2 year(s) of age? [If no, no further questions.]	Yes	No
29	Has the patient tried at least one conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months? [Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.] [If yes, skip to question 31.]	Yes	No
30	Has documentation been provided to confirm that the patient had an intolerance to at least two conventional synthetic DMARDs? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.] [If no, no further questions.]	Yes	No
31	Has documentation been provided to confirm that the patient had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitors, Enbrel (etanercept) and an adalimumab product (Hadlima, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
32	Has documentation been provided to confirm that the patient had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred JAK inhibitor, Xeljanz? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
33	Is this medication being prescribed by or in consultation with a rheumatologist or a dermatologist?	Yes	No

maryland physicians care
Medicaid with a Heart

PRIOR AUTHORIZATION REQUEST

	[If no, no further questions.]		
34	Does the requested dose exceed FDA approved label dosing for the requested indication? [No further questions.]	Yes	No
35	Is the patient greater than or equal to 18 year(s) of age? [If no, no further questions.]	Yes	No
36	Is this medication being prescribed by or in consultation a dermatologist? [If no, no further questions.]	Yes	No
37	Has the patient tried at least ONE other therapy for at least 3 months? [Note: Examples include intralesional or oral corticosteroids (such as triamcinolone, prednisone), systemic antibiotics (for example, clindamycin, dicloxacillin, erythromycin), or isotretinoin.] [If no, no further questions.]	Yes	No
38	Has documentation been provided to confirm that the patient had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitor, adalimumab products? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
39	Does the requested dose exceed FDA approved label dosing for the requested indication?	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

If you have any questions, call: 1-888-258-8250

PRIOR AUTHORIZATION REQUEST

If you have any questions, call:
1-888-258-8250